The global Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 9,954,720.47 thousand by 2030, from USD 4,577,440.16 thousand in 2022, growing at the CAGR of 10.6% in the forecast period of 2023 to 2030. Market Segmentation Global Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina, Peru, Rest of South America - Industry Trends and Forecast to 2030 Overview of Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics Driver • Increasing prevalence and incidence of acute lung injury in the market Restraint • High cost of device and treatment Opportunity • Strategic initiatives joined with new product launches by market players Market Players Some of the major market players operating in the global Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • Drägerwerk AG & Co. KGaA • NIPRO • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • WEINMANN Emergency Medical Technology GmbH + Co. KG • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd. • Besmed Health Business Corp.

1 INTRODUCTION 41 1.1 OBJECTIVES OF THE STUDY 41 1.2 MARKET DEFINITION 41 1.3 OVERVIEW OF GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41 1.4 LIMITATIONS 43 1.5 MARKETS COVERED 43 2 MARKET SEGMENTATION 45 2.1 MARKETS COVERED 45 2.2 GEOGRAPHICAL SCOPE 46 2.3 YEARS CONSIDERED FOR THE STUDY 47 2.4 CURRENCY AND PRICING 47 2.5 DBMR TRIPOD DATA VALIDATION MODEL 48 2.6 MULTIVARIATE MODELLING 51 2.7 TYPE LIFELINE CURVE 51 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52 2.9 DBMR MARKET POSITION GRID 53 2.10 MARKET END USER COVERAGE GRID 54 2.11 VENDOR SHARE ANALYSIS 55 2.12 SECONDARY SOURCES 56 2.13 ASSUMPTIONS 56 3 EXECUTIVE SUMMARY 57 4 PREMIUM INSIGHTS 60 4.1 PESTEL ANALYSIS 61 4.2 PORTER’S FIVE FORCES 62 4.3 INSURANCE REIMBURSEMENT 63 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 63 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 63 4.3.3 ABBOTT CODING GUIDE FOR ECMO 64 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 64 4.3.5 CERN HEALTH INSURANCE SCHEME 65 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 65 4.3.7 AMERICAN HOSPITAL ASSOCIATION 66 4.4 PIPELINE ANALYSIS 67 4.5 PRICING ANALYSIS 69 5 MARKET OVERVIEW 70 5.1 DRIVERS 72 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 72 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 72 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 73 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 73 5.2 RESTRAINTS 74 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 74 5.2.2 HIGH COST OF DEVICES AND TREATMENT 74 5.3 OPPORTUNITIES 75 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 75 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 75 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 76 5.4 CHALLENGES 77 5.4.1 STRINGENT RULES & REGULATIONS 77 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 78 6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 79 6.1 OVERVIEW 80 6.2 MECHANICAL VENTILATION 83 6.2.1 HIGH-FLOW NASAL O2 84 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 84 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 84 6.2.4 PRONE POSITION VENTILATION 84 6.2.5 OTHERS 85 6.3 CORTICOSTEROIDS 85 6.3.1 METHYLPREDNISOLONE 86 6.3.2 DEXAMETHASONE 86 6.3.3 OTHERS 86 6.4 ANTIVIRAL MEDICATION 87 6.4.1 RIBAVIRIN 88 6.4.2 OSELTAMIVIR 88 6.4.3 OTHERS 88 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 88 6.6 TOCILIZUMAB 89 6.7 OTHERS 89 7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 90 7.1 OVERVIEW 91 7.2 SEPSIS 94 7.3 INHALATION OF HARMFUL SUBSTANCES 94 7.4 SEVERE PNEUMONIA 95 7.5 OTHERS 95 8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 96 8.1 OVERVIEW 97 8.2 PARENTERAL 100 8.2.1 INTRAVENOUS 100 8.2.2 INTRAMUSCULAR 100 8.3 ORAL 101 8.4 OTHERS 101 9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 102 9.1 OVERVIEW 103 9.2 HOSPITALS 106 9.3 SPECIALTY CLINICS 106 9.4 HOME HEALTHCARE 107 9.5 OTHERS 107 10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 108 10.1 OVERVIEW 109 10.2 DIRECT TENDER 112 10.3 HOSPITAL PHARMACY 112 10.4 RETAIL PHARMACY 113 10.5 ONLINE PHARMACY 113 11 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 114 11.1 OVERVIEW 115 11.2 NORTH AMERICA 118 11.2.1 U.S 123 11.2.2 CANADA 128 11.2.3 MEXICO 133 11.3 EUROPE 138 11.3.1 GERMANY 143 11.3.2 FRANCE 148 11.3.3 U.K 153 11.3.4 ITALY 158 11.3.5 SPAIN 163 11.3.6 TURKEY 168 11.3.7 NETHERLANDS 173 11.3.8 SWITZERLAND 178 11.3.9 BELGIUM 183 11.3.10 RUSSIA 188 11.3.11 REST OF EUROPE 193 11.4 ASIA-PACIFIC 194 11.4.1 JAPAN 200 11.4.2 CHINA 205 11.4.3 INDIA 210 11.4.4 SOUTH KOREA 215 11.4.5 AUSTRALIA 220 11.4.6 SINGAPORE 225 11.4.7 THAILAND 230 11.4.8 MALAYSIA 235 11.4.9 INDONESIA 240 11.4.10 PHILIPPINES 245 11.4.11 REST OF ASIA-PACIFIC 250 11.5 SOUTH AMERICA 251 11.5.1 BRAZIL 256 11.5.2 ARGENTINA 261 11.5.3 REST OF SOUTH AMERICA 266 11.6 MIDDLE EAST AND AFRICA 267 11.6.1 SOUTH AFRICA 272 11.6.2 SAUDI ARABIA 277 11.6.3 U.A.E 282 11.6.4 ISRAEL 287 11.6.5 EGYPT 292 11.6.6 KUWAIT 297 11.6.7 REST OF MIDDLE EAST AND AFRICA 302 12 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 303 12.1 COMPANY SHARE ANALYSIS: GLOBAL 303 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304 12.3 COMPANY SHARE ANALYSIS: EUROPE 305 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306 13 SWOT ANALYSIS 307 14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 308 14.1 GILEAD SCIENCES INC 308 14.1.1 COMPANY SNAPSHOT 308 14.1.2 REVENUE ANALYSIS 309 14.1.3 COMPANY SHARE ANALYSIS 309 14.1.4 PRODUCT PORTFOLIO 310 14.1.5 RECENT DEVELOPMENT 310 14.2 TERUMO CORPORATION 311 14.2.1 COMPANY SNAPSHOT 311 14.2.2 REVENUE ANALYSIS 311 14.2.3 COMPANY SHARE ANALYSIS 312 14.2.4 PRODUCT PORTFOLIO 312 14.2.5 RECENT DEVELOPMENT 312 14.3 GETINGE 313 14.3.1 COMPANY SNAPSHOT 313 14.3.2 REVENUE ANALYSIS 313 14.3.3 COMPANY SHARE ANALYSIS 314 14.3.4 PRODUCT PORTFOLIO 314 14.3.5 RECENT DEVELOPMENT 314 14.4 LIVANOVA PLC 315 14.4.1 COMPANY SNAPSHOT 315 14.4.2 REVENUE ANALYSIS 315 14.4.3 COMPANY SHARE ANALYSIS 316 14.4.4 PRODUCT PORTFOLIO 316 14.4.5 RECENT DEVELOPMENTS 316 14.5 MEDTRONIC 317 14.5.1 COMPANY SNAPSHOT 317 14.5.2 REVENUE ANALYSIS 317 14.5.3 COMPANY SHARE ANALYSIS 318 14.5.4 PRODUCT PORTFOLIO 318 14.5.5 RECENT DEVELOPMENTS 318 14.6 ARMSTRONG MEDICAL 319 14.6.1 COMPANY SNAPSHOT 319 14.6.2 PRODUCT PORTFOLIO 319 14.6.3 RECENT DEVELOPMENT 319 14.7 BESMED HEALTH BUSINESS CORP 320 14.7.1 COMPANY SNAPSHOT 320 14.7.2 PRODUCT PORTFOLIO 320 14.7.3 RECENT DEVELOPMENTS 321 14.8 DRÄGERWERK AG & CO. KGAA 322 14.8.1 COMPANY SNAPSHOT 322 14.8.2 REVENUE ANALYSIS 322 14.8.3 PRODUCT PORTFOLIO 323 14.8.4 RECENT DEVELOPMENTS 323 14.9 EUROSETS 324 14.9.1 COMPANY SNAPSHOT 324 14.9.2 PRODUCT PORTFOLIO 324 14.9.3 RECENT DEVELOPMENT 324 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 325 14.10.1 COMPANY SNAPSHOT 325 14.10.2 REVENUE ANALYSIS 325 14.10.3 PRODUCT PORTFOLIO 326 14.10.4 RECENT DEVELOPMENTS 326 14.11 FRESENIUS SE & CO. KGAA 327 14.11.1 COMPANY SNAPSHOT 327 14.11.2 REVENUE ANALYSIS 327 14.11.3 PRODUCT PORTFOLIO 328 14.11.4 RECENT DEVELOPMENT 328 14.12 HAMILTON MEDICAL 329 14.12.1 COMPANY SNAPSHOT 329 14.12.2 PRODUCT PORTFOLIO 329 14.12.3 RECENT DEVELOPMENT 329 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 330 14.13.1 COMPANY SNAPSHOT 330 14.13.2 PRODUCT PORTFOLIO 330 14.13.3 RECENT DEVELOPMENT 330 14.14 NIPRO 331 14.14.1 COMPANY SNAPSHOT 331 14.14.2 REVENUE ANALYSIS 331 14.14.3 PRODUCT PORTFOLIO 332 14.14.4 RECENT DEVELOPMENT 332 14.15 PFIZER INC 333 14.15.1 COMPANY SNAPSHOT 333 14.15.2 REVENUE ANALYSIS 333 14.15.3 PRODUCT PORTFOLIO 334 14.15.4 RECENT DEVELOPMENT 334 14.16 RESMED 335 14.16.1 COMPANY SNAPSHOT 335 14.16.2 REVENUE ANALYSIS 335 14.16.3 PRODUCT PORTFOLIO 336 14.16.4 RECENT DEVELOPMENT 336 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 337 14.17.1 COMPANY SNAPSHOT 337 14.17.2 PRODUCT PORTFOLIO 337 14.17.3 RECENT DEVELOPMENT 337 15 QUESTIONNAIRE 338 16 RELATED REPORTS 341